California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...
We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t ...
Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback